Key Insights from Attending ASH 2025
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Key Insights from Attending ASH 2025
-
Narrated by:
-
Written by:
About this listen
Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC
Recorded on December 18, 2025
Lore Gruenbaum, PhD
Chief Scientific Officer & Senior Vice President of Research
Blood Cancer United
Washington, DC
Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know!
Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
No reviews yet